amounts of Baht 542 million and Baht 533.31 million, respectively, which decreased by 1.6% compared to the total revenue. The revenue from In-patients department declined by 8.4% y-o-y. There are three main
treatment for the 3rd quarter of Year 2018 and 2019 were in amounts of Baht 154.39 million and Baht 207.0 million, respectively, which increased by Baht 50.61 million or in the proportion of 34.1%. These
explain our 2017’s second quarter operating performance compared to 2016’s second quarter operating performance accordingly as below; Revenue from sales for the second quarter of 2017 and 2016 was for
and 238.21 million baht respectively, increased by 136.88 million baht or 57.46%. 2. The commission and brokerage income in this year was 99.57 million baht, decreased from last year 40.57 million baht
27.63 million and THB 2.23 million respectively or equivalent to 297.10% and 314.08% respectively due to installation solar cell project 1 MW and warehouse tenants increased. Gross Profit / Margin The
investor contact? and ?Category B investor contact? will be changed to ?investment analyst? and ?investment consultant,? respectively. For transitional period, presently approved ?Category A investor contact
clarify operating performance of the Company for the yearly ending 31 December 2019 as the following: The Company earned THB 795.3 MB and THB 871.0 MB in the year 2019 and 2018 respectively, A decrease in
the deviation of AdjRW recorded in the past. The amount of Baht 14.92, and 18.81 million for diagnosis related group (DRG) received in year 2013 and 2015 respectively and the amount of Baht 8.46 million
years ending 31 December 2016 and 2017, total revenue increased from THB 2,181.9 Mn to THB 2,515.2 Mn respectively. This was an increase of THB 333.3 Mn or 15.3% and was mainly due to the increased